Characteristics and outcome of patients with dual hepatitis B and C-associated hepatocellular carcinoma: Are they different from patients with single virus infection?

Liver International

Volumn 29, Issue 5, 2009, Pages 767-773

  Huo, Teh Ia ^a,b   Huang, Yi Hsiang ^a,b   Hsia, Cheng Yuan ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Hsu, Chia Yang ^a,b   Lee, Pui Ching ^a   Lui, Wing Yiu ^a,b   Loong, Che Chuan ^a,b   Chiang, Jen Huei ^a,b   Chiou, Yi You ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

ACETIC ACID; ALCOHOL; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; SEX RATIO; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAIWAN;

EID: 64749092294     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01908.x     Document Type: Article

References (38)

1. El-Serag HB, Davila JA, Petersen NJ, et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003; 139: 817-23.
2. Pocobelli G, Cook LS, Brant R, et al. Hepatocellular carcinoma incidence trends in Canada: Analysis by birth cohort and period of diagnosis. Liver Int 2008; 28: 1272-9.
3. Gelatti U, Donato F, Tagger A, et al. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol 2003; 98: 907-14.
4. Tan A, Yeh SH, Liu CJ, et al. Viral hepatocarcinogenesis: From infection to cancer. Liver Int 2008; 28: 175-88.
5. Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin Liver Dis 2005; 25: 143-54.
6. Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(Suppl. 1):2-15.
7. Trevisani F, Magini G, Santi V, et al. Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol 2007; 102: 1022-31.
8. Lee SD, Lo KJ, Tsai YT, et al. Maternal hepatitis B virus DNA in mother-infant transmission. Lancet 1989; 1: 719.
9. Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 2002;37(Suppl. 13):65-8.
10. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126: 1024-9.
11. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
12. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
13. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
14. Llovet JM, BrúC, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
16. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
17. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
18. Huo TI, Wu JC, Lui WY, et al. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol 2004; 99: 1479-87.
19. Lei HJ, Chau GY, Lui WY, et al. Prognostic value and clinical relevance of the 6th edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 2006; 203: 426-35.
20. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
21. Huo TI, Huang YH, Lin HC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006; 101: 975-82.
22. Huo TI, Lin HC, Huang YH, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107: 141-8.
23. Huo TI, Huang YH, Wu JC. Percutaneous ablation therapy for hepatocellular carcinoma: Current practice and future perspectives. J Chin Med Assoc 2005; 68: 155-9.
24. Huo TI, Wu JC, Hsia CY, et al. Hepatitis C virus infection is a risk factor for tumor recurrence after resection of small hepatocellular carcinomas. World J Surg 2004; 28: 787-91.
25. Lee SD, Lee FY, Wu JC, et al. The prevalence of anti-hepatitis C virus among Chinese patients with hepatocellular carcinoma. Cancer 1992; 69: 342-5.
26. Benvegnù L, Alberti A. Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. Antiviral Res 2001; 52: 199-207.
27. Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26: 2166-76.
28. Liaw YF, Tsai SL, Chang JJ, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994; 106: 1048-53.
29. Sheen IS, Liaw YF, Lin DY, et al. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis 1994; 170: 358-61.
30. Liaw YF, Tsai SL, Sheen IS, et al. Clinical and virological course of chronic hepatitis B virus infection with hepatitis C and D virus markers. Am J Gastroenterol 1998; 93: 354-9.
31. Chen MF, Jeng LB, Lee WC. Surgical results in patients with hepatitis virus-related hepatocellular carcinoma in Taiwan. World J Surg 2002; 26: 742-7.
32. Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 2978-80.
33. Yu MW, Chang HC, Chang SC, et al. Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 2003; 38: 1393-400.
34. Toso C, Trotter J, Wei A, et al. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-15.
35. Chau GY, Lui WY, Wu CW. Spectrum and significance of microscopic vascular invasion in hepatocellular carcinoma. Surg Oncol Clin North Am 2003; 12: 25-34.
36. Martins A, Cortez-Pinto H, Marques-Vidal P, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int 2006; 26: 680-7.
37. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97: 1042-50.
38. Huang YH, Wu JC, Chen CH, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int 2005; 25: 236-41.